UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The Journal of infectious diseases, ISSN 0022-1899, 04/2016, Volume 213, Issue 8, pp. 1240 - 1247
sofosbuvir | L159F | V321A | direct-acting antivirals | resistance | HCV NS5B sofosbuvir resistance-associated variants | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Hepatitis C - drug therapy | Antiviral Agents - therapeutic use | Humans | Hepacivirus - genetics | Sequence Analysis, RNA | Molecular Epidemiology | Antiviral Agents - adverse effects | Hepatitis C - epidemiology | Hepatitis C - virology | Drug Resistance, Viral - drug effects | High-Throughput Nucleotide Sequencing | Sofosbuvir - adverse effects | Genotype | Care and treatment | Interferon | Dosage and administration | Research | Hepatitis C | Index Medicus | Abridged Index Medicus | Major and Brief Reports | HCV NS5B sofosbuvir resistance–associated variants
Journal Article
Clinical infectious diseases, ISSN 1058-4838, 2016, Volume 63, Issue 11, pp. 1479 - 1481
OST | HCV | Velpatasvir | Sofosbuvir | PWID | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Carbamates - administration & dosage | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Adult | Female | Opiate Substitution Treatment | Sofosbuvir - adverse effects | Drug Therapy, Combination | Hepacivirus - drug effects | Heterocyclic Compounds, 4 or More Rings - administration & dosage | Sofosbuvir - therapeutic use | Liver Cirrhosis - drug therapy | Data Interpretation, Statistical | Drug Administration Schedule | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Genotype | Heterocyclic Compounds, 4 or More Rings - adverse effects | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Hepatitis C, Chronic - blood | Medication Adherence | Sofosbuvir - administration & dosage | Antiviral Agents - adverse effects | Carbamates - adverse effects | Sustained Virologic Response | Carbamates - therapeutic use | Hepatitis C, Chronic - genetics | Treatment outcome | Hepatitis C | Drug therapy | Analysis | Prescription drugs | Hepatitis | Substance abuse treatment | Safety | Index Medicus | sofosbuvir | Brief Reports | velpatasvir
Journal Article
Life sciences (1973), ISSN 0024-3205, 05/2020, Volume 248, pp. 117477 - 6
COVID-19 | Structural bioinformatics | Wuhan coronavirus | Nucleotide inhibitors | RdRp | Docking | Sofosbuvir | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Guanosine Monophosphate - chemistry | Uridine Triphosphate - metabolism | Coronavirus Infections - drug therapy | Humans | Pneumonia, Viral - drug therapy | RNA Replicase - metabolism | Adenosine Monophosphate - chemistry | Betacoronavirus - enzymology | Sofosbuvir - metabolism | Alanine - chemistry | Alphacoronavirus - enzymology | RNA Replicase - antagonists & inhibitors | Guanosine Triphosphate - metabolism | Antiviral Agents - metabolism | Viral Proteins - metabolism | Alanine - analogs & derivatives | Thermodynamics | Alphacoronavirus - genetics | Antiviral Agents - chemistry | Guanosine Monophosphate - analogs & derivatives | Guanosine Triphosphate - chemistry | Protein Interaction Domains and Motifs | Amino Acid Sequence | Protein Conformation, alpha-Helical | Catalytic Domain | Computational Biology - methods | Adenosine Monophosphate - metabolism | Viral Proteins - chemistry | Alanine - metabolism | Viral Proteins - antagonists & inhibitors | Ribavirin - metabolism | Uridine Triphosphate - chemistry | Ribavirin - chemistry | Sequence Homology, Amino Acid | Sequence Alignment | Coronavirus Infections - virology | Protein Conformation, beta-Strand | Guanosine Monophosphate - metabolism | RNA Replicase - chemistry | Adenosine Monophosphate - analogs & derivatives | Drug Repositioning - methods | Protein Binding | Molecular Docking Simulation | Betacoronavirus - genetics | Pneumonia, Viral - virology | Sofosbuvir - chemistry | Drugs | Disease transmission | Nucleotide sequence | Viral diseases | Fatalities | Coronaviruses | RNA polymerase | Nucleotides | DNA-directed RNA polymerase | Ribavirin | Index Medicus
Journal Article
Clinical infectious diseases, ISSN 1058-4838, 06/2016, Volume 62, Issue 12, pp. 1489 - 1496
HIV-HCV | sofosbuvir | coinfection | antiretroviral therapy | daclatasvir | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | HIV-1 | Hepatitis C - drug therapy | Coinfection - drug therapy | Humans | Middle Aged | Imidazoles - administration & dosage | Male | Viral Load | Young Adult | Adult | Female | Imidazoles - therapeutic use | Sofosbuvir - adverse effects | Drug Therapy, Combination | Sofosbuvir - therapeutic use | Antiviral Agents - therapeutic use | HIV Infections - virology | Imidazoles - adverse effects | Antiviral Agents - administration & dosage | Coinfection - virology | Sofosbuvir - administration & dosage | Antiviral Agents - adverse effects | Hepatitis C - virology | HIV Infections - drug therapy | Aged | Hepacivirus | Antiviral agents | Hepatitis | Usage | Care and treatment | Comorbidity | Analysis | Antiretroviral drugs | Viruses | Drug therapy | Product safety | Human immunodeficiency virus--HIV | Index Medicus | and Commentaries
Journal Article
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2017, Volume 153, Issue 1, pp. 113 - 122
Gastroenterology and Hepatology | Direct-Acting Antiviral Agent | Shortened Duration Therapy | Clinical Trial | Comparison | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Humans | Middle Aged | Male | Carbamates - administration & dosage | Young Adult | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Aged, 80 and over | Adult | Female | Sofosbuvir - adverse effects | Drug Therapy, Combination | Heterocyclic Compounds, 4 or More Rings - administration & dosage | Sofosbuvir - therapeutic use | Antiviral Agents - therapeutic use | Heterocyclic Compounds, 4 or More Rings - adverse effects | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Macrocyclic Compounds - therapeutic use | Sofosbuvir - administration & dosage | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Macrocyclic Compounds - administration & dosage | Sustained Virologic Response | Carbamates - therapeutic use | Sulfonamides - administration & dosage | Medical colleges | Care and treatment | Protease inhibitors | Proteases | Transplantation of organs, tissues, etc | Product development | Hepatitis C virus | Hepatitis C | Health aspects | Analysis | Index Medicus | Abridged Index Medicus
Journal Article
Haemophilia : the official journal of the World Federation of Hemophilia, ISSN 1351-8216, 03/2017, Volume 23, Issue 2, pp. 198 - 206
sofosbuvir | hepatitis C virus | NS5A inhibitor | ribavirin | NS5B inhibitor | ledipasvir–sofosbuvir fixed‐dose combination | ledipasvir–sofosbuvir fixed-dose combination | Life Sciences & Biomedicine | Hematology | Science & Technology | Sofosbuvir - therapeutic use | Antiviral Agents - therapeutic use | Humans | Middle Aged | Ribavirin - therapeutic use | Fluorenes - therapeutic use | Male | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Young Adult | Benzimidazoles - administration & dosage | Sofosbuvir - administration & dosage | Ribavirin - administration & dosage | Adult | Female | Fluorenes - administration & dosage | Aged | Drug Combinations | Benzimidazoles - therapeutic use | Complications and side effects | Care and treatment | Mortality | Hemophilia | Blood diseases | Hepatitis C | Hepatitis C virus | Liver cirrhosis | Ribavirin | Headache | Liver | Diarrhea | Chronic infection | Fatigue | Infections | Nausea | Bleeding | Sleep disorders | Genotype & phenotype | Hepatitis | Interferon | Index Medicus
Journal Article
The American journal of gastroenterology, ISSN 0002-9270, 10/2017, Volume 112, p. S535
Journal Article
Antiviral research, ISSN 0166-3542, 01/2017, Volume 137, pp. 134 - 140
Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | Virology | Sofosbuvir - therapeutic use | Cell Line | Zika Virus Infection - drug therapy | Antiviral Agents - pharmacology | Sofosbuvir - pharmacology | Administration, Oral | Antiviral Agents - therapeutic use | United States | Humans | Zika Virus - drug effects | Drug Approval | Zika Virus Infection - virology | Animals | Sofosbuvir - administration & dosage | Mice | Drug Evaluation, Preclinical | United States Food and Drug Administration | Antiviral agents | Medical colleges | Genetic disorders | Microbiology | Guillain-Barre syndrome | Birth defects | Drug approval | Virus diseases | Prevention | Stem cell research | Hepatitis | Immunotherapy | Stem cells | Drug therapy | Hepatitis C virus | Health aspects | Biomedical engineering | Index Medicus
Journal Article
Clinical infectious diseases, ISSN 1058-4838, 10/2015, Volume 61, Issue 8, pp. 1304 - 1306
BRIEF REPORTS | Simeprevir | HBV/HCV coinfection | Acute hepatitis | HBV reactivation | Sofosbuvir | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Sofosbuvir - therapeutic use | Coinfection | Administration, Oral | Antiviral Agents - therapeutic use | Humans | Middle Aged | Risk Factors | Hepatitis B - virology | Hepatitis C, Chronic - virology | Male | Hepatitis C, Chronic - complications | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Hepatitis B virus - physiology | Simeprevir - therapeutic use | Hepatitis B - complications | Simeprevir - administration & dosage | Sofosbuvir - administration & dosage | Drug Therapy, Combination | Hepatitis | Care and treatment | Research | Hepatitis C virus | Disease prevention | Infectious diseases | Antibiotics | Drug therapy | Patients | Index Medicus
Journal Article
Digestive and liver disease, ISSN 1590-8658, 02/2019, Volume 51, Issue 2, pp. 258 - 262
Journal Article
Journal of hepatology, ISSN 0168-8278, 2015, Volume 63, Issue 3, pp. 581 - 585
Gastroenterology and Hepatology | Antiviral agents | Hepatitis C | Polymerase inhibitor | Sofosbuvir | Egypt | Genotype 4 | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Genotype | Male | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Sofosbuvir - administration & dosage | Ribavirin - adverse effects | Ribavirin - administration & dosage | Adult | Female | Aged | Sofosbuvir - adverse effects | Drug Therapy, Combination | Care and treatment | Genetic aspects | Hepatitis C virus | Health aspects | Ribavirin | Index Medicus
Journal Article
Journal of hepatology, ISSN 0168-8278, 2014, Volume 62, Issue 5, pp. 1040 - 1046
Gastroenterology and Hepatology | Hepatitis C virus | Direct-acting antiviral | Egyptian | Sofosbuvir | Interferon-free therapy | Genotype 4 | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | United States | Humans | Middle Aged | Egypt | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | RNA Replicase - antagonists & inhibitors | Hepatitis C, Chronic - ethnology | Ribavirin - administration & dosage | Adult | Female | Sofosbuvir - adverse effects | Hepacivirus - drug effects | RNA, Viral - analysis | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Drug Therapy, Combination - methods | Sofosbuvir - administration & dosage | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Aged | Viral Load - drug effects | Viral Load - methods | Viral Nonstructural Proteins - antagonists & inhibitors | Virus diseases | Care and treatment | Genetic aspects | Health aspects | Ribavirin | Index Medicus
Journal Article